Emel Mashaki Ceyhan Appointed Market Access, Regulatory Affairs & Corporate Affairs Director at Takeda Türkiye

Takeda continues its operations in Turkey successfully, and through its human resources policies, it ensures that successful Turkish executives take positions in international roles while continuing to strengthen Turkey's management with experienced names from the pharmaceutical sector.

Emel Mashaki Ceyhan, who has over 16 years of experience in prestigious pharmaceutical companies, has started her role as Director of Market Access, Regulatory Affairs and Corporate Relations at Takeda Turkey.

Emel Mashaki Ceyhan, who graduated from Istanbul University Faculty of Pharmacy in 2002, completed her master's studies in 2006 simultaneously at Marmara University in Pharmacology / Clinical Pharmacy and at Yeditepe University in Business and Healthcare Management.

Continuing the Business and Strategic Management Doctoral program at Bilgi University between 2008-2011, she completed her doctorate in Pharmaceutical Sciences and Drug Policy at Cardiff University in the United Kingdom in 2017 with a thesis examining the processes of drug registration and access in Turkey.

Ceyhan began her professional career at HEXAL (Sandoz) in the Regulatory Affairs & Research & Development unit, and served as Pharmacovigilance Country Manager at Bristol-Myers Squibb between 2006 and 2010.

Between 2010 and 2015, she held global responsibilities as Regional Regulatory Affairs Manager at Novo Nordisk Middle East Regional Office and as Clinical Development & Regulatory Affairs Manager at the Novo Nordisk headquarters in Denmark.

In 2015, she joined Alexion as Pharmaceutical and Regulatory Affairs Director, managing different functions such as Regulatory Affairs, Market Access, Pharmacovigilance and Quality, and served on the management team.

Emel Mashaki Ceyhan served as Lecturer in Clinical Pharmacy at Yeditepe University between 2003 and 2006. She currently participates in important committees within AIFD and conducts important and strategic work at CIRS (Centre for Innovation In Regulatory Science), a UK-based organization that conducts scientific studies with leading health and reimbursement authorities worldwide, to improve drug registration and patient medication access processes in Turkey.

Emel Mashaki Ceyhan continues academic and educational work on pharmaceutical legislation and regulatory affairs at university level, and has numerous scientific studies and articles published in international peer-reviewed journals both domestically and internationally.